Ordering
Available Variants25 mg
CHA.60001-25mg
Price
€194.40
Available – Dispatch in 14 days
100 mg
CHA.60001-100mg
Price
€347.20
Available – Dispatch in 14 days
25 g
CHA.60001-25g
Price
€352.80
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.60001-25mg | €194.40 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
100 mg | CHA.60001-100mg | €347.20 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 g | CHA.60001-25g | €352.80 |
≥98% (HPLC), powder, sodium channel blocker
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C17H20F6N2O3 · C2H4O2 |
|---|---|
| CAS Number | 54143-56-5 |
| Molecular Weight | 474.39 |
| NACRES | NA.77 |
| PubChem Substance ID | 24278440 |
| UNSPSC Code | 12352200 |
| EC Number | 258-997-5 |
| MDL number | MFCD00214290 |
| Quality level | 200 |
Safety Information Handling visibility
| pictograms |
GHS08
GHS07
  GHS08,GHS07
|
|---|---|
| signalword | Danger |
| hcodes | H302,H315,H319,H335,H360FD |
| pcodes | P202 - P261 - P301 + P312 - P302 + P352 - P305 + P351 + P338 - P308 + P313 |
| Hazard Classifications | Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3 |
| target_organs | Respiratory system |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Flecainide acetate salt, with a CAS number of 3094-87-9, is a pharmaceutical compound utilized in the management of certain cardiac arrhythmias. As a class IC antiarrhythmic agent, it functions by inhibiting sodium channels in the heart, thereby slowing the conduction velocity of electrical impulses and prolonging the refractory period. This mechanism of action is effective in treating supraventricular tachycardia, including atrial fibrillation and flutter, as well as ventricular arrhythmias. Flecainide acetate salt is administered orally and is known for its high bioavailability, allowing for effective plasma concentrations to be achieved. Its pharmacokinetic profile is characterized by extensive tissue distribution and a relatively long half-life, enabling once or twice daily dosing regimens. The compounds efficacy and safety profile make it a valuable option for the treatment of various arrhythmic conditions.
